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of the study is that the safety data were obtained from clinical trials rather than 
actual clinical practice with these drugs.
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Objectives: 2011 AHA and 2012 ESC guidelines recommend antiplatelet therapy 
at presentation for suspected ACS patients. For CABG patients (approximately 10% 
of ACS presentations) this strategy creates a dilemma: delay CABG to washout anti-
platelet therapy or perform surgery and risk bleeding. Bridging strategies have been 
proposed using GPIs. Cangrelor, a novel reversible, IV P2Y12 inhibitor with rapid 
onset/offset, demonstrated in the CHAMPION PHOENIX trial a reduction in ischemic 
events vs. clopidogrel in patients undergoing PCI. Adoption of cangrelor for angiog-
raphy in ACS patients eliminates the need to washout an oral P2Y12inhibitor in case 
of unanticipated CABG. The aim of our analysis was to quantify the annual value of 
this pathway change to a US hospital. MethOds: A decision analytic model based 
on the current CABG patient pathway was developed to quantify the value of a 
reduction in bridging by adopting cangrelor from a US hospital perspective. Premier 
hospital database informed the timing of CABG after washout; demographics, drug-
mix, LOS, blood product utilization, and hospital ward costs. Ischemic event rates 
and costs were informed by published sources. Drug costs were 2014 wholesale 
acquisition costs. Cangrelor cost was set to $0. Results: For a hypothetical US 
hospital treating 195 CABG patients/year (patient mix: 4% STE-ACS, 26% NSTE-ACS, 
70% SA), shifting away from bridging with GPI by adopting cangrelor resulted in a 
total annual cost reduction of $120,000. Total costs in the base-case are estimated 
to be $2.95MM vs. the scenario case of $2.83MM. Cost savings were derived from 
eliminating GPI utilization, lowering washout drug costs and reducing hospitaliza-
tion days. cOnclusiOns: Removal of the need to washout oral antiplatelet therapy 
prior to CABG through adoption of cangrelor is estimated to deliver a clinical value 
of ~$615/CABG patient with fewer total days spent hospitalized.
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Objectives: To analyse the budgetary impact (BI) of the introduction of NOAC 
in patients with NVAF compared to warfarin treatment scenario (DC) from the 
perspective of the public health system of Extremadura (PHSE). MethOds: 
A budget impact study was performed during 2013. It was based on anticoagulant 
therapy (AO) on patients with NVAF. The data came from the electronic clinical his-
tory called JARA®. Pharmaceutical costs associated to the control and monitoring 
of patients with DC were included. Specifically those related to the incidence of 
stroke (CVA), gastrointestinal haemorrhage (HG), intracranial haemorrhage (ICH) 
and acute myocardial infarction (AMI) as the RE-LY, ROCKET and ARISTOTLE trials. 
For DC, there were taken into account the best and worst scenario. The pharmaceu-
tical cost considered was the sum of the official price and the VAT. To other public 
health costs, official prices from the PHSE and the Spanish National Health Care 
System were considered. Results: Treatment distribution among patients was 
92.63% DC; 4.02% Dabigatran (DAB); 3.07% rivaroxaban (RIV) and 0.28% Apixaban 
(APX). The total expenditure for the AO patients with VKA in the best scenario is 
€ 3,036,604.28 (average cost per patient: € 342.11, CI 95%: 341.89 - 342.34) and the 
worst would be € 3,727,169 (€ 419.92, CI 95%: 419.70 - 420.15). For NOAC the results 
are € 572,515.39 (€ 810.93, CI 95%I: 786.71 - 835.16). NOAC represent the 71.44% of the 
pharmaceutical expenditure (PE), the 23.47% of PE’s control and monitoring of DC 
and the 15.86% of the total expenditure from AO patients with NVAF, in the best sce-
nario. cOnclusiOns: The market access of NOAC has been modest and similar to 
the rest of Spain. AVK alternative has the lowest average cost per patient. Limitation: 
safety data has been obtained from clinical trials instead of using clinical practice.
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Objectives: Updated treatment guidelines for atrial fibrillation (AF) have been 
released by the National Institute for Health and Care Excellence (NICE) in the 
United Kingdom and highlight a current shortfall in the prescribing of anticoagu-
lants to patients with AF despite the importance of stroke prevention. A model 
was designed for use as a planning tool for Clinical Commissioning Groups (CCGs) 
looking to budget for the future move towards full implementation of the NICE 
guidelines. MethOds: An Excel model was developed to estimate the 5-year 
impact of gradually treating all eligible AF patients who are currently not being 
prescribed anticoagulants, both in terms of the effect on clinical outcomes (strokes, 
major bleeds and mortality) and the financial impact associated with treating more 
patients. Assumptions had to be made in order to simplify the model and populate 
default values. Risks of clinical outcomes were taken from a literature search. Costs 
were taken from published national sources. Results: In an average sized CCG 
(population of 226,000) the model estimated that in order to gradually treat the full 
eligible AF patient population, an additional budget of £103,899 will be required in 
Year 1 to treat an additional 248 patients, rising to £791,076 in Year 5 to treat an 
additional 1,889 patients. Cumulatively over the 5-year timeframe this could lead 
to the prevention of 8 ischemic strokes and 3 deaths, as well as an increase of 2 
haemorrhagic strokes and 8 bleeds. cOnclusiOns: The clinical benefits of appro-
living and mobility. Botulinum neurotoxin-A (BoNT-A) injections are effective in 
treating ULS. We aimed to calculate annual BoNT-A treatment cost of ULS on a 
per-patient basis, and the expected overall annual budget impact of BoNT-A treat-
ment in Germany using static and dynamic market share scenarios. MethOds: 
A budget impact model for BoNT-A use, adopting a German health care system 
perspective, was developed. Two market-share scenarios were modelled over 5 years. 
While the static scenario assumed current market shares (abobotulinumtoxinA, 
36%; onabotulinumtoxinA, 26%; incobotulinumtoxinA, 38%) to remain constant over 
time, the dynamic scenario assumed market share of abobotulinumtoxinA to rise 
up to 76% across 5 years. Epidemiologic data inputs were sourced from the most 
recently published literature, unit costs for BoNT-As from the Lauertaxe (pharmacy 
purchase price [PPP] level), and market share assumptions from IMS Health (Market 
Sizing). Equivalence of the 3 BoNTAs in terms of efficacy and safety is assumed and 
therefore no differential use of medical services or other goods. Results: Annual 
BoNT-A drug costs per ULS patient were 3 463€ , 5 603€ , and 5 410€ , respectively, 
with prescribing patterns following SmPC recommendations for abobotulinum-
toxinA, onabotulinumtoxinA, and incobotulinumtoxinA. The total drug costs were 
decreased by between 1 231 861€ (-4%) in year 2 and 5 133 684€ (-17%) in year 5 by 
shifting the market share to abobotulinumtoxinA. Sensitivity analyses showed that 
the number of patients treated with BoNT-As, time to re-injection, and dose per 
injection were the most influential parameters on budget impact, impacting both 
drug acquisition costs and physician visits. cOnclusiOns: Increased use of abo-
botulinumtoxinA compared with incobotulinumtoxinA and onabotulinumtoxinA 
for ULS in Germany could potentially reduce the total cost of treatment.
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Objectives: Renal denervation (RDN) is a new treatment option for patients with 
uncontrolled resistant hypertension. Studies have shown RDN to have a potential 
reduction in systolic blood pressure and therefore reduce risk for different cerebro-
cardiovascular disease (stroke, ischemic heart disease, heart failure, etc.). The aim is 
to assess the economic impact of renal denervation in resistant hypertensive patients 
based on the potential clinical benefit demonstrated in literature. MethOds: 
A budget impact model was developed to quantify RDN-related cost-savings accom-
plished through lower rate of cerebro-cardiovascular events compared with the 
medical treatment cohort (with 3+ anti-hypertensive medications including a diu-
retic). The model was developed from the Italian National Healthcare Service (NHS) 
perspective with a 10-year time horizon. The risk of events was calculated using 
different multivariate equations. A literature review was carried out to collect the 
treatment costs for both acute and chronic phase of hypertension-related events. 
The cost of RDN procedure was approximated to the related DRG tariff. Results: 
Renal denervation, considering the blood pressure reduction observed after pro-
cedure, substantially reduces cerebro-cardiovascular event probabilities by 30% if 
compared to the medical treatment cohort. Assuming a yearly 2% RDN adoption 
rate, approximately 2,000 events would be avoided in 10 years allowing total savings 
up to 9 Million euro. The higher cost of new technology was offset from potential 
saving associated to the avoided events. Compared to the total costs associated 
to the medical treatment cohort in 10 years the overall expenditure for RDN was 
greater than 0.8%. The annual incremental cost for patients treated with surgical 
approach was estimated at 16 euro per patient. cOnclusiOns:  The economic 
impact of hypertension-related complications is significant in the Italian setting. 
Consequently the potential savings according to the NHS perspective derived from 
the implementation of strategies aimed at improving the level of hypertension 
should be considered.
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Objectives: To estimate the costs associated with the use of dabigatran (DB) vs. 
dicoumarins (DC) in non-valvular atrial fibrillation (NVAF) from the perspective 
of the Extremadura Public Health System (EPHS) in 2013. MethOds: A budget 
impact study of anticoagulant therapy (AT) with DB and DC in patients with NVAF 
was carried out during 2013. The data were processed using the JARA® electronic 
record application. Pharmaceutical costs and costs associated with patient follow-
up and monitoring were included. Costs relating to incidence of stroke, gastroin-
testinal bleeding, intracranial haemorrhage and acute myocardial infarction were 
also included based on RE-LY clinical trials. For pharmaceutical cost RRP + VAT of 
the medicinal products was used, and other health care costs were based on the 
public prices of the EPHS and the National Health System. Results: Three hun-
dred eighty-five patients were treated with DB (4.01 %) and 8876 with DC (92.63%). 
Mean age was 77 (95 % CI: 76.82-77.19). Total expenditure for AT with AVK for the 
best case scenario would be € 3,036,604.28 (mean cost per patient: € 342.11; 95% 
CI: 341.80-342.34) and the worst case € 3,727,169.83 (€ 419.92; 95% CI: 419.70-419.15) 
and for DB € 318,077.15 (mean expenditure: € 826.27; 95% CI: 796.81-855.57). For a 
DB market penetration of 50%, expenditure on anticoagulation of these patients 
would be € 3,958,659.57 while for 75% it would be € 5,937,989.36. cOnclusiOns: 
Dabigatran is a more costly option than classic treatment with DC. In 2013 this drug’s 
market penetration was limited and was closer to other estimates. Estimated mean 
cost per patient for DCs is similar to the estimates of other communities (Basque 
Country: € 300-700 and the Valencian Community: € 300) and are somewhat lower 
for DB (Basque Country: € 1,197 and the Valencian Community: € 1,350). A limitation 
